An EMA official confirms the existence of a “link“between the AstraZeneca vaccine and the cases of thrombosis observed after its administration, in an interview with the Italian daily Il Messaggero published on March 6, 2021.
An abnormally high number of cases of cerebral thrombosis in young people
“Now we can tell, it is clear that there is a link with the vaccine. What causes this reaction, however, we don’t know yet.“says Marco Cavaleri, head of vaccine strategy at the European Medicines Agency (EMA).”To sum up, in the next few hours we will say that there is a connection, but we still have to figure out how it happens.“, he adds, while the EMA must meet on the file from April 6 to 9.”We are trying to get a precise picture of what is happening, to define precisely this syndrome due to the vaccine (…) Among the vaccinated people, there is a number of cases of cerebral thrombosis in young people higher than this. what we would expect. This we will have to say“, he again declared.
Image capture, December 21, 2020, of Marco Cavaleri, during an online press conference in Amsterdam. Credit: ANP / AFP / Archives – Pieter Stam de Jonge
Dozens of cases have already been identified
For several weeks, suspicions have appeared on possible serious side effects, but rare, after the observation in people vaccinated with AstraZeneca of cases of atypical thrombosis. Dozens of cases have already been identified, several of which have resulted in death. In the UK, there have been 30 cases and seven deaths out of a total of 18.1 million doses administered as of March 24. So far, the EMA has maintained that “no causal link with the vaccine is proven“, even if it is”possible“, and that the benefits of vaccination against the coronavirus always outweigh the risks. For Paul Hunter, a specialist in medical microbiology at the University of East Anglia interviewed by AFP,”rather, the evidence points to the Oxford-AstraZeneca vaccine as the cause“.
As a precaution, several countries have decided to no longer administer this vaccine below a certain age, such as France, Germany and Canada. Norway and Denmark have suspended its use altogether for now. For its part, AstraZeneca assured in March that there was “no evidence of increased risk“, and assured that”patient safety“constituted his”main priority“.